drugset / Trial / NCT05157178
Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.
Phase 4
Unknown
1264 enrolled
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
RandomizedParallel-groupOpen-labelPrevention
Summary
The purpose of this clinical trial is to compare antibody response and safety of the Covid-19 (recombinante) vaccine according to different time intervals between the first two doses (4, 8 and 12 weeks) and serologic status immediately before the vaccine.
Timeline
- Start
- 2021-07-20
- Primary completion
- 2022-03-31
- Completion
- 2023-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Covid-19 (recombinante) vaccine | Vaccine | — | — |